Compare TEVA & FTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TEVA | FTS |
|---|---|---|
| Founded | 1901 | 1885 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2B | 26.0B |
| IPO Year | N/A | N/A |
| Metric | TEVA | FTS |
|---|---|---|
| Price | $28.38 | $51.19 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 1 |
| Target Price | $27.00 | ★ $72.00 |
| AVG Volume (30 Days) | ★ 11.4M | 756.4K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 3.47% |
| EPS Growth | N/A | ★ 4.08 |
| EPS | 0.62 | ★ 2.41 |
| Revenue | ★ $16,776,000,000.00 | $8,643,898,655.00 |
| Revenue This Year | $4.74 | $13.04 |
| Revenue Next Year | $0.48 | $4.82 |
| P/E Ratio | $46.12 | ★ $21.10 |
| Revenue Growth | 0.02 | ★ 5.21 |
| 52 Week Low | $12.47 | $40.32 |
| 52 Week High | $28.68 | $52.83 |
| Indicator | TEVA | FTS |
|---|---|---|
| Relative Strength Index (RSI) | 80.93 | 45.70 |
| Support Level | $24.01 | $51.10 |
| Resistance Level | $26.96 | $52.56 |
| Average True Range (ATR) | 0.68 | 0.63 |
| MACD | 0.19 | -0.14 |
| Stochastic Oscillator | 94.65 | 18.47 |
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Fortis owns and operates eight utility transmission and distribution subsidiaries in Canada and the United States, serving roughly 3.5 million electricity and gas customers. The company has smaller stakes in electricity generation and several Caribbean utilities. Subsidiary ITC operates electric transmission in seven US states, with more than 16,000 miles of high-voltage transmission lines in operation.